Apremilast: A Phosphodiesterase 4 Inhibitor for the Treatment of Psoriatic Arthritis.

ABSTRACT:

Introduction

Psoriatic arthritis (PsA) is a spondyloarthritis that occurs in up to 30% of psoriasis patients. Patients with PsA are at risk for decreased quality of life due to both joint and skin symptoms, impaired physical function and disease progression. Treatments include non-steroidal anti-inflammatory drugs, conventional systemic disease-modifying anti-rheumatic drugs (DMARDs) such as methotrexate, and biologic agents, including tumor necrosis factor-α inhibitors. The most recently introduced treatment option is apremilast, an oral phosphodiesterase 4 inhibitor.

Methods

This review provides an in-depth discussion of apremilast's mechanism of action, and evidence of its clinical efficacy and safety from the Psoriatic Arthritis Long-term Assessment of Clinical Efficacy

SUBMITTER: Mease PJ 

PROVIDER: S-EPMC4883260 | biostudies-literature | 2014 Dec

REPOSITORIES: biostudies-literature